Effects of adenosine analogs on inositol 1,4,5-trisphosphate production in porcine coronary artery

Worku Abebe, S. Jamal Mustafa

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Using various pharmacological methods, we previously demonstrated that the smooth muscle and endothelium of porcine coronary artery contain vasorelaxant adenosine A2 receptors, which are predominantly the A2A subtype. The present study was intended to investigate the effect of adenosine receptor stimulation on agonist-induced inositol 1,4,5-trisphosphate (IP3) generation in porcine coronary artery using the nonselective adenosine analogs, 2-chloroadenosine (CAD) and 5′-(N-ethylcarboxamido)adenosine (NECA), and the A2A selective analog 2-p-(2-carboxyethyl)-phenethylamino-5′-N-ethylcarboxamidoadenosine (CGS). In both endothelium-intact and denuded coronary artery rings, CAD, NECA and CGS elicited a dose-dependent inhibition of prostaglandin F (PG)-induced IP3 production. However, the inhibitory effect of NECA was relatively less in endothelium-denuded preparations. The nonselective xanthine adenosine receptor antagonist, 8-sulfophenyltheophylline (8-SPT), significantly attenuated the IP3-inhibitory effect of CAD and, to a lesser extent, that of NECA. Further, the A2A selective nonxanthine antagonist, 5-amino-7-(2-phenylethyl)-2-(-furyl)-pyrazolo[4,3]-1,2,4-triazolo[1,5-c] pyrimidine (SCH), markedly decreased the effects of all CAD, NECA and CGS on PG-induced IP3 generation. These results provide evidence that activation of adenosine A2 receptors by CAD, NECA and CGS in porcine coronary artery causes inhibition of agonist-induced IP3 production, and these receptors involve at least the A2A subtype.

Original languageEnglish (US)
Pages (from-to)89-95
Number of pages7
JournalVascular Pharmacology
Volume39
Issue number1-2
DOIs
StatePublished - Jul 1 2002

Fingerprint

Inositol 1,4,5-Trisphosphate
Adenosine
Coronary Vessels
Swine
Adenosine A2 Receptors
Endothelium
Dinoprost
2-Chloroadenosine
Purinergic P1 Receptor Antagonists
Inositol 1,4,5-Trisphosphate Receptors
Purinergic P1 Receptors
Xanthine
Vasodilator Agents
Smooth Muscle
Pharmacology

Keywords

  • Adenosine A receptors
  • Adenosine analogs
  • Inositol 1,4,5-trisphosphate
  • Porcine coronary artery

ASJC Scopus subject areas

  • Pharmacology

Cite this

Effects of adenosine analogs on inositol 1,4,5-trisphosphate production in porcine coronary artery. / Abebe, Worku; Mustafa, S. Jamal.

In: Vascular Pharmacology, Vol. 39, No. 1-2, 01.07.2002, p. 89-95.

Research output: Contribution to journalArticle

@article{08710c26f0094b76820ebefb4a8d4e1f,
title = "Effects of adenosine analogs on inositol 1,4,5-trisphosphate production in porcine coronary artery",
abstract = "Using various pharmacological methods, we previously demonstrated that the smooth muscle and endothelium of porcine coronary artery contain vasorelaxant adenosine A2 receptors, which are predominantly the A2A subtype. The present study was intended to investigate the effect of adenosine receptor stimulation on agonist-induced inositol 1,4,5-trisphosphate (IP3) generation in porcine coronary artery using the nonselective adenosine analogs, 2-chloroadenosine (CAD) and 5′-(N-ethylcarboxamido)adenosine (NECA), and the A2A selective analog 2-p-(2-carboxyethyl)-phenethylamino-5′-N-ethylcarboxamidoadenosine (CGS). In both endothelium-intact and denuded coronary artery rings, CAD, NECA and CGS elicited a dose-dependent inhibition of prostaglandin F2α (PG)-induced IP3 production. However, the inhibitory effect of NECA was relatively less in endothelium-denuded preparations. The nonselective xanthine adenosine receptor antagonist, 8-sulfophenyltheophylline (8-SPT), significantly attenuated the IP3-inhibitory effect of CAD and, to a lesser extent, that of NECA. Further, the A2A selective nonxanthine antagonist, 5-amino-7-(2-phenylethyl)-2-(-furyl)-pyrazolo[4,3]-1,2,4-triazolo[1,5-c] pyrimidine (SCH), markedly decreased the effects of all CAD, NECA and CGS on PG-induced IP3 generation. These results provide evidence that activation of adenosine A2 receptors by CAD, NECA and CGS in porcine coronary artery causes inhibition of agonist-induced IP3 production, and these receptors involve at least the A2A subtype.",
keywords = "Adenosine A receptors, Adenosine analogs, Inositol 1,4,5-trisphosphate, Porcine coronary artery",
author = "Worku Abebe and Mustafa, {S. Jamal}",
year = "2002",
month = "7",
day = "1",
doi = "10.1016/S1537-1891(02)00277-X",
language = "English (US)",
volume = "39",
pages = "89--95",
journal = "Vascular Pharmacology",
issn = "1537-1891",
publisher = "Elsevier Inc.",
number = "1-2",

}

TY - JOUR

T1 - Effects of adenosine analogs on inositol 1,4,5-trisphosphate production in porcine coronary artery

AU - Abebe, Worku

AU - Mustafa, S. Jamal

PY - 2002/7/1

Y1 - 2002/7/1

N2 - Using various pharmacological methods, we previously demonstrated that the smooth muscle and endothelium of porcine coronary artery contain vasorelaxant adenosine A2 receptors, which are predominantly the A2A subtype. The present study was intended to investigate the effect of adenosine receptor stimulation on agonist-induced inositol 1,4,5-trisphosphate (IP3) generation in porcine coronary artery using the nonselective adenosine analogs, 2-chloroadenosine (CAD) and 5′-(N-ethylcarboxamido)adenosine (NECA), and the A2A selective analog 2-p-(2-carboxyethyl)-phenethylamino-5′-N-ethylcarboxamidoadenosine (CGS). In both endothelium-intact and denuded coronary artery rings, CAD, NECA and CGS elicited a dose-dependent inhibition of prostaglandin F2α (PG)-induced IP3 production. However, the inhibitory effect of NECA was relatively less in endothelium-denuded preparations. The nonselective xanthine adenosine receptor antagonist, 8-sulfophenyltheophylline (8-SPT), significantly attenuated the IP3-inhibitory effect of CAD and, to a lesser extent, that of NECA. Further, the A2A selective nonxanthine antagonist, 5-amino-7-(2-phenylethyl)-2-(-furyl)-pyrazolo[4,3]-1,2,4-triazolo[1,5-c] pyrimidine (SCH), markedly decreased the effects of all CAD, NECA and CGS on PG-induced IP3 generation. These results provide evidence that activation of adenosine A2 receptors by CAD, NECA and CGS in porcine coronary artery causes inhibition of agonist-induced IP3 production, and these receptors involve at least the A2A subtype.

AB - Using various pharmacological methods, we previously demonstrated that the smooth muscle and endothelium of porcine coronary artery contain vasorelaxant adenosine A2 receptors, which are predominantly the A2A subtype. The present study was intended to investigate the effect of adenosine receptor stimulation on agonist-induced inositol 1,4,5-trisphosphate (IP3) generation in porcine coronary artery using the nonselective adenosine analogs, 2-chloroadenosine (CAD) and 5′-(N-ethylcarboxamido)adenosine (NECA), and the A2A selective analog 2-p-(2-carboxyethyl)-phenethylamino-5′-N-ethylcarboxamidoadenosine (CGS). In both endothelium-intact and denuded coronary artery rings, CAD, NECA and CGS elicited a dose-dependent inhibition of prostaglandin F2α (PG)-induced IP3 production. However, the inhibitory effect of NECA was relatively less in endothelium-denuded preparations. The nonselective xanthine adenosine receptor antagonist, 8-sulfophenyltheophylline (8-SPT), significantly attenuated the IP3-inhibitory effect of CAD and, to a lesser extent, that of NECA. Further, the A2A selective nonxanthine antagonist, 5-amino-7-(2-phenylethyl)-2-(-furyl)-pyrazolo[4,3]-1,2,4-triazolo[1,5-c] pyrimidine (SCH), markedly decreased the effects of all CAD, NECA and CGS on PG-induced IP3 generation. These results provide evidence that activation of adenosine A2 receptors by CAD, NECA and CGS in porcine coronary artery causes inhibition of agonist-induced IP3 production, and these receptors involve at least the A2A subtype.

KW - Adenosine A receptors

KW - Adenosine analogs

KW - Inositol 1,4,5-trisphosphate

KW - Porcine coronary artery

UR - http://www.scopus.com/inward/record.url?scp=0036665629&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036665629&partnerID=8YFLogxK

U2 - 10.1016/S1537-1891(02)00277-X

DO - 10.1016/S1537-1891(02)00277-X

M3 - Article

VL - 39

SP - 89

EP - 95

JO - Vascular Pharmacology

JF - Vascular Pharmacology

SN - 1537-1891

IS - 1-2

ER -